alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015279EN.01002801.xml

| 24.8.2015 | EN | Official Journal of the European Union | C 279/28 |
| --- | --- | --- | --- |

24.8.2015

EN

Official Journal of the European Union

C 279/28

---

Judgment of the General Court of 6 July 2015 — France v Commission

(Case T-516/10) (1)

((EAGGF - ‘Guidance’ Section - Reduction of financial aid - Community initiative programme Leader+ - Failure to comply with the time-limit for adoption of a decision - Infringement of an essential procedural requirement))

(2015/C 279/33)

Language of the case: French

Parties

Applicant: French Republic (represented initially by: E Belliard, B. Cabouat, G. de Bergues, D. Colas and C. Candat, and subsequently by: D. Colas, C. Candat and J.-S. Pilczer, acting as Agents)

Defendant: European Commission (represented by: D. Bianchi and G. von Rintelen, acting as Agents)

Re:

Annulment of Commission Decision C(2010) 5724 Final of 23 August 2010 on the application of financial corrections to assistance from the EAGGF, ‘guidance’ section, allocated to the Community initiative programme CCI 2000.FR.060.PC.001 (France — Leader+)

Operative part of the judgment

The Court:

| 1. | Annuls Commission Decision C(2010) 5724 Final of 23 August 2010 on the application of financial corrections to assistance from the EAGGF, ‘guidance’ section, allocated to the Community initiative programme CCI 2000.FR.060.PC.001 (France — Leader+); |
| --- | --- |

1.

Annuls Commission Decision C(2010) 5724 Final of 23 August 2010 on the application of financial corrections to assistance from the EAGGF, ‘guidance’ section, allocated to the Community initiative programme CCI 2000.FR.060.PC.001 (France — Leader+);

| 2. | Orders the European Commission to bear its own costs and to pay those incurred by the French Republic. |
| --- | --- |

2.

Orders the European Commission to bear its own costs and to pay those incurred by the French Republic.

---

(1)  
  OJ C 13, 15.1.2011.

---
#### § 555.7 Official seals; forms, use, and breaking.

The official seals required by this part are those prescribed in § 541.3 and § 312.5 of this chapter.
# C_2010288EN.01006201.xml

| 23.10.2010 | EN | Official Journal of the European Union | C 288/62 |
| --- | --- | --- | --- |

23.10.2010

EN

Official Journal of the European Union

C 288/62

---

Action brought on 30 August 2010 — Rubinetterie Teorema v Commission

(Case T-370/10)

()

(2010/C 288/111)

Language of the case: Italian

Parties

Applicant: Rubinetterie Teorema SpA (Flero, Brescia, Italy) (represented by: R. Cavani, lawyer, M. Di Muro, lawyer, P. Preda, lawyer)

Defendant: European Commission

Form of order sought

| — | Annul Decision C(2010) 4185 of 23 June 2010; |
| --- | --- |

—

Annul Decision C(2010) 4185 of 23 June 2010;

| — | In the alternative, impose a token fine; |
| --- | --- |

—

In the alternative, impose a token fine;

| — | In the further alternative, substantially reduce the fine imposed by the decision to such amount as the Court deems appropriate; |
| --- | --- |

—

In the further alternative, substantially reduce the fine imposed by the decision to such amount as the Court deems appropriate;

| — | Order the Commission to pay the costs. |
| --- | --- |

—

Order the Commission to pay the costs.

Pleas in law and main arguments

The decision contested in these proceedings is the same as that contested in Case T-368/10 Rubinetteria Cisal v Commission.

The pleas in law and main arguments are similar to those relied on in that case.

In particular, the applicant alleges:

| — | Infringement of the rights of the defence in relation to Teorema and the consequent invalidity of the decision owing to:






  — | the delay in communicating to Teorema the accusations made by the Commission; |
| --- | --- | --- |

—

Infringement of the rights of the defence in relation to Teorema and the consequent invalidity of the decision owing to:

—

the delay in communicating to Teorema the accusations made by the Commission;

| — | the difficulties in accessing the file and the lack of an adequate extension of the time-limits; |
| --- | --- |

—

the difficulties in accessing the file and the lack of an adequate extension of the time-limits;

| — | The fact that there is no agreement whose purpose or effect is to prevent, restrict or distort competition and/or no adverse effects on Community trade, and |
| --- | --- |

—

The fact that there is no agreement whose purpose or effect is to prevent, restrict or distort competition and/or no adverse effects on Community trade, and

| — | The incorrect assessment of the evidence relating to the alleged involvement of Teorema in Euroitalia’s meetings. |
| --- | --- |

—

The incorrect assessment of the evidence relating to the alleged involvement of Teorema in Euroitalia’s meetings.

---
UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)November 26,
2008




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
            
            000-23143
            
            13-3379479(State
      or other jurisdiction
              of
      incorporation)
            
            (Commission
              File
      Number)
            
            (IRS
      Employer
              Identification
      No.)777 Old Saw Mill River
      Road, Tarrytown, New York
            
            10591(Address
      of principal executive offices)
            
            (Zip
      Code)Registrant's telephone number,
      including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))




oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))











Item
8.01. Other Events.





On
November 26, 2008, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that a phase 3 clinical
study investigating RELISTOR®(methylnaltrexone bromide) subcutaneous injection to treat opioid-induced
constipation in patients with chronic, non-cancer pain achieved statistical
significance for the primary and key secondaryefficacy
endpoints. Adverse events observed in this study were similar to those seen in
prior studies of subcutaneous RELISTOR. The positive outcome reported was from
the double-blind, randomized placebo-controlled portion of a phase 3 clinical
study.





A copy of
the press release is attached hereto as Exhibit 99.1 and the information
contained therein is incorporated by reference into this Item 8.01 of this
Current Report on Form 8-K.




Item
9.01   Financial Statements and Exhibits.




(d)
Exhibits





Exhibit
No.     Description




99.1
            Press
      Release dated November 26, 2008.







SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.






PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A.
McKinney


Chief Financial Officer, Senior
Vice President,


Finance & Operations and
Treasurer








Date:November26, 2008
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Eye Institute Special Emphasis Panel, NEI Clinical Applications II.                    

*Date:*                         April 11, 2011.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Anne E. Schaffner, PhD, Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301-451-2020,                         *aes@nei.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: March 4, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011-5507 Filed 3-9-11; 8:45 am]

BILLING CODE 4140-01-P
Appellant’s Motion Granted; Appellee’s Motion Denied as Moot; Appeal

Dismissed and Memo randum Opinion filed November 15 , 2016

.

In The 

## Fourteenth Court of Appeals

NO. 14

- 16

- 00300

- CV

IN THE MATTER OF THE MARRIAGE OF VICTOR E . UWA AND

IDONGESIT PAMELA UDO H

- UWA

On Appeal from the 309th District Court

Harris County, Texas Trial Court Cause No. 2014

- 48637

M E M O R A N D U M O P I N I O N This is an appeal from a judgment signed March 8, 2016. On Octob er 12, 2016, appellee filed a motion to dismiss the appeal for want of prosecution. On October 24, 2016, appellant filed a motion to withdraw his notice of appeal. See Tex. R. App. P. 42.1. Appellant’s motion is granted. Appellee’s motion is denied

as moot

. Accordingly, the appeal is ordered dismissed.

PER CURIAM
Panel consists of Chief Justice Frost and Justices McCally and Brown.
### §5309. Omitted

#### **Editorial Notes**

#### Codification

Section, Pub. L. 101–425, §10, Oct. 15, 1990, 104 Stat. 919, which required, at the time the President's annual budget request for the Department is submitted, that the Secretary provide to Congress a detailed review of the progress of the research and development activities authorized under this chapter, terminated, effective May 15, 2000, pursuant to section 3003 of Pub. L. 104–66, as amended, set out as a note under section 1113 of Title 31, Money and Finance. See, also, page 84 of House Document No. 103–7.
EXHIBIT 23.1

                         CONSENT OF INDEPENDENT AUDITORS


We  hereby  consent  to the  incorporation  by  reference  in  the  Registration
Statements  on Form S-8 (No.  333-73454 and  333-56432) of Asante  Technologies,
Inc. of our report  dated  November 1, 2002,  except for Note 9, as to which the
date is March 13,  2003,  Note 8 as to which the date is  November  30, 2003 and
Notes 1 and 2, as to  which  the  date is  December  30,  2003  relating  to the
financial statements and financial statement schedule, which appear in this Form
10-K/A.


PricewaterhouseCoopers LLP
San Jose, California
January 2, 2004
Exhibit 99.3



CERTIFICATION PURSUANT TO 18 U.S.C.
SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of CellStar Corporation
(the Registrant) on Form 10-K for the fiscal year ended November 30, 2002, as filed with the Securities and Exchange Commission on February 28, 2003, as amended by Amendment No. 1 on Form 10-K/A, filed with the Securities and Exchange
Commission on March 31, 2003 and Amendment No. 2 on Form 10-K/A, filed with the Securities and Exchange Commission on the date hereof (collectively, the Report), the undersigned hereby certifies, in the capacity as indicated below
and pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:



| | 1. |  | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | -- |  | ---------------------------------------------------------------------------------------------------------------------------------



| | 2. |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| | -- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Robert A.
Kaiser

Robert A. Kaiser, Chief Executive Officer

Date: April 25, 2003
#### § 341.7 Concurrences.

Concurrences must be shown in the carrier's tariff and maintained consistent with the requirements of Part 341 of this chapter.

[Order 780, 78 FR 32099, May 29, 2013]
# C_2012194EN.01000801.xml

| 30.6.2012 | EN | Official Journal of the European Union | C 194/8 |
| --- | --- | --- | --- |

30.6.2012

EN

Official Journal of the European Union

C 194/8

---

Order of the Court (Fifth Chamber) of 29 March 2012 — Lancôme parfums et beauté & Cie v Office for Harmonisation in the Internal Market (Trade Marks and Designs), Focus Magazin Verlag GmbH

(Case C-334/11 P) (1)

1

(Appeal - Community trade mark - Word mark ACNO FOCUS - Opposition by the proprietor of the national word mark FOCUS - Refusal of registration - Article 43(2) and (3) of Regulation (EC) No 40/94 - Earlier mark registered for not less than five years)

2012/C 194/13

Language of the case: English

Parties

Parties

Appellant: Lancôme parfums et beauté & Cie (represented by: A. von Mühlendahl, Rechtsanwalt)

Appellant:

Other parties to the proceedings: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: G. Schneider, acting as Agent), Focus Magazin Verlag GmbH (represented by: R. Schweizer and J. Berlinger, Rechtsanwälte)

Other parties to the proceedings:

Re:

Re:

Appeal against the judgment of the General Court (Eighth Chamber) of 14 April 2011 in Case T-466/08 Lancôme v OHIM by which that Court dismissed an action for annulment brought by the applicant for the word mark ‘ACNO FOCUS’ for goods in Class 3 against the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (OHIM) of 29 July 2008 in Case R 1796/2007-1 dismissing the appeal against the Opposition Division’s decision refusing registration of that mark in the opposition proceedings brought by the proprietor of the national word mark ‘FOCUS’ for goods and services in Classes 3, 5, 6, 7, 8, 9, 14, 15, 16, 18, 20, 21, 24, 25, 26, 28, 29, 30, 33, 34, 36, 38, 39, 41 and 42 — Interpretation and application of Article 43(2) and (3) of Regulation No 40/94 (now Article 42(2) and (3) of Regulation No 207/2009) — Meaning of genuine use of a trade mark

Lancôme

OHIM

Operative part of the order

Operative part of the order

The Court (Fifth Chamber):

| 1. | Dismisses the appeal; |
| --- | --- |

1.

Dismisses the appeal;

| 2. | Orders Lancôme parfums et beauté & Cie to pay the costs. |
| --- | --- |

2.

Orders Lancôme parfums et beauté & Cie to pay the costs.

---

(1)  OJ C 282, 24.9.2011.

1

---
# C_2011030EN.01004301.xml

| 29.1.2011 | EN | Official Journal of the European Union | C 30/43 |
| --- | --- | --- | --- |

29.1.2011

EN

Official Journal of the European Union

C 30/43

---

Action brought on 22 November 2010 — Häfele v OHIM (Vorfront)

(Case T-531/10)

()

2011/C 30/78

Language in which the application was lodged: German

Parties

Parties

Applicant: Häfele GmbH & Co. KG (Nagold, Germany) (represented by M. Eck and J. Dönch, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 September 2010 in Case R 570/2010-1; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 September 2010 in Case R 570/2010-1;

| — | Order the Office for Harmonisation in the Internal Market to pay the costs. |
| --- | --- |

—

Order the Office for Harmonisation in the Internal Market to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: the word mark ‘Vorfront’ for goods in Classes 6, 7, 19 and 20.

Community trade mark concerned:

Decision of the Examiner: refusal to register

Decision of the Examiner:

Decision of the Board of Appeal: dismissal of the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 7(1)(b) and (c) of Regulation (EC) No 207/2009 (1), as the Community trade mark in question has distinctive character and is not purely descriptive

Pleas in law:

1

---

(1)  Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (OJ 2009 L 78, p. 1).

1

---
EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Annual Report on Form 10-K of WNC Housing Tax
Credit Fund IV, L.P., Series 1 (the  "Partnership") for the year ended March 31,
2004 as filed with the  Securities  and Exchange  Commission  on the date hereof
(the "Report"),  and pursuant to 18 U.S.C., section 1350, as adopted pursuant to
section  906 of the  Sarbanes-Oxley  Act of  2002,  I,  Thomas  J.  Riha,  Chief
Financial Officer of WNC & Associates, Inc., general partner of the Partnership,
hereby certify that:

          1.   The Report fully complies with the  requirements of section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

          2.   The information  contained in the Report fairly presents,  in all
               material  respects,   the  financial   condition  and  result  of
               operations of the Partnership.


/s/THOMAS J. RIHA
-----------------
Thomas J. Riha
Senior Vice President and Chief Financial Officer of WNC & Associates, Inc.
July 14, 2004
### **CHAPTER 57—INTERSTATE HORSERACING**

Sec.
3001.
Congressional findings and policy.
3002.
Definitions.
3003.
Acceptance of interstate off-track wager.
3004.
Regulation of interstate off-track wagering.
3005.
Liability and damages.
3006.
Civil action.
3007.
Jurisdiction and venue.
Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Service Bancorp, Inc. (the Company) on Form 10-QSB for the quarter ended March 31, 2004 as filed
with the Securities and Exchange Commission on the date hereof (the Report), I, Dana S. Philbrook, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



This certification is provided solely pursuant to 18 U.S.C. Section 1350 and
Item 601(b)(32) of Regulation S-K (Item 601(b)(32)) promulgated under the Securities Act of 1933 (the Securities Act) and the Securities Exchange Act of 1934 (the Exchange Act). In accordance with clause (ii) of
Item 601(b)(32), this certification (A) shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any
filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.



|                       
|-----------------------
|/s/ DANA S. PHILBROOK  
|Dana S. Philbrook      
|Chief Financial Officer



May 14, 2004
§ 1307.8 Compliance information. ( a ) *Cooperation and assistance.* TVA shall to the fullest extent practicable seek the cooperation of recipients in obtaining compliance with this part and shall provide assistance and guidance to recipients to help them comply voluntarily with this part.
( b ) *Compliance reports.* Each recipient shall keep such records and submit to TVA timely, complete and accurate compliance reports at such times, and in such form and containing such information, as TVA may determine to be necessary to enable it to ascertain whether the recipient has complied or is complying with this part. In the case which a primary recipient extends financial assistance to any other recipient, such other recipient shall also submit such compliance reports to the primary recipient as may be necessary to enable the primary recipient to carry out its obligations under this part.
( c ) *Access to sources of information.* Each recipient shall permit access by TVA during normal business hours to such of its books, records, accounts, and other sources of information, and its facilities, as TVA may require to ascertain compliance with this part. Where any information required of a recipient is in the exclusive possession of any other agency, institution or person and this agency, institution or person shall fail or refuse to furnish this information, the recipient shall so certify in its report and set forth the efforts it has made to obtain the information.
( d ) *Information to employees, beneficiaries and participants.* Each recipient shall make available to employees, participants, beneficiaries, and other interested persons such information regarding the provisions of this part and its applicability to the program or activity for which the recipient receives financial assistance, and shall make such information available to them in such manner, as TVA finds necessary to apprise such persons of the protections against discrimination assured them by section 504 and this part.
[45 FR 22895, Apr. 4, 1980, as amended at 68 FR 51356, Aug. 26, 2003]